There are serious doubts about whether the FDA will approve Biogen’s Alzheimer’s candidate aducanumab – but is gearing up to file it with the regulator and is already looking ahead to a pot
Patients in England are to get easier access to Merck KGaA’s multiple sclerosis drug Mavenclad after NICE dropped requirements for a special MRI scan before prescription.
